MK-677 vs Ipamorelin: Oral vs Injectable GH

MK-677 is a non-peptide, orally active ghrelin mimetic developed by Merck. It binds the ghrelin receptor (GHS-R1a) and stimulates growth hormone release from the pituitary gland. A single 25 mg oral dose sustains elevated GH and IGF-1 for a full 24 hours.

It is not a peptide. It is not a SARM, despite frequent mislabeling on supplement websites. MK-677 is a small molecule with oral bioavailability above 60% (Murphy et al., J Clin Endocrinol Metab, 1998).

In healthy elderly subjects, 25 mg/day for 4 weeks restored IGF-1 levels to the range of young adults (Chapman et al., J Clin Endocrinol Metab, 1996). A 12-month study confirmed sustained fat-free mass increases but also documented insulin resistance as the primary safety concern (Nass et al., 2008).

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that earned the title "first selective growth hormone secretagogue" in the landmark Raun et al. study. It stimulates GH release through the ghrelin receptor, but with a selectivity profile unlike any other compound in its class.

At doses up to 200 times the effective threshold, ipamorelin does not elevate cortisol, ACTH, prolactin, FSH, LH, or TSH (Raun et al., Endocrinology, 1998). No other GH secretagogue achieves this level of selectivity.

Its half-life is approximately 2 hours, producing a single GH peak at about 40 minutes post-injection that declines exponentially (Johansen et al., Eur J Clin Pharmacol, 1999). Standard dosing is 100-300 mcg subcutaneously, typically paired with CJC-1295 for synergistic GHRH-GHRP activation.

Both compounds target the ghrelin receptor on the pituitary gland. The difference lies in activation pattern and downstream effects.

Both compounds raise GH and IGF-1 meaningfully, but the pattern and magnitude differ.

MK-677 at 25 mg/day restored IGF-1 in elderly subjects to levels matching young adults (a 40-60% increase from baseline) within 2 weeks. After 12 months of continuous use, IGF-1 remained elevated and fat-free mass increased significantly by DXA scan (Nass et al., 2008). In obese subjects, 2 months of MK-677 increased fat-free mass and basal energy expenditure (Murphy et al., 1998).

Ipamorelin produces dose-proportional GH peaks at approximately 40 minutes post-injection. The GH pulse is sharp and resolves within 4-6 hours. Direct body composition studies for ipamorelin alone are limited; most clinical use pairs it with CJC-1295, and the combination data is more robust.

For sustained GH and IGF-1 elevation with clinical documentation, MK-677 has more published evidence. For pulsatile, physiological GH release with a cleaner side effect profile, ipamorelin paired with CJC-1295 is the standard approach.

This is where the two compounds diverge sharply. MK-677 carries metabolic risks that ipamorelin does not.

Both compounds are popular for sleep improvement. MK-677 has a specific advantage here: a dedicated PubMed study on sleep architecture.

Copinschi et al. (1997) administered MK-677 to young men and found a 50% increase in Stage IV (deep) sleep duration and a 20% increase in REM sleep. Total sleep time was not changed, but the quality of sleep shifted toward more restorative stages (Copinschi et al., Neuroendocrinology, 1997).

Ipamorelin lacks a dedicated sleep study. Users commonly report improved sleep quality, deeper rest, and more vivid dreams, consistent with GH-mediated sleep enhancement. The mechanism is sound: GH secretion naturally peaks during deep sleep, and ipamorelin amplifies this pulse when injected before bed.

For documented sleep improvement, MK-677 has the stronger evidence base. For those who prioritize safety and minimal metabolic impact, ipamorelin before bed is the conservative choice. For a broader overview of sleep-targeting peptides, see our peptides for sleep guide.

MK-677 has the most direct body composition evidence among non-prescription GH secretagogues.

The Nass 2008 twelve-month study measured body composition by DXA in healthy elderly subjects. MK-677 at 25 mg/day produced statistically significant increases in fat-free mass. Limb fat also increased. Total body weight rose, partly from water retention and lean tissue. Notably, grip strength and physical function did not improve despite the body composition changes (Nass et al., 2008).

In obese subjects, Murphy et al. (1998) documented increased fat-free mass and basal metabolic rate after 2 months of MK-677. The combination of higher lean mass and higher energy expenditure is favorable for recomposition, though the insulin resistance signal complicates this picture for long-term use.

Ipamorelin standalone body composition data is limited. The CJC-1295/ipamorelin combination is the standard clinical protocol, and most practitioners report improvements in fat loss, recovery, and lean tissue over 8-12 week cycles. See our CJC-1295/ipamorelin benefits guide for combination data.

MK-677 is cheaper and more convenient. This explains its popularity despite the metabolic risks.

MK-677 requires zero injection supplies and no reconstitution. You swallow a capsule once daily. For people who cannot tolerate needles, this is a significant advantage. Ipamorelin requires purchasing bacteriostatic water, insulin syringes, and the peptide vial, then reconstituting and injecting subcutaneously 1-3 times daily.

Both compounds are research chemicals without FDA approval. Neither is legally marketed for human therapeutic use. MK-677 is sometimes sold as a dietary supplement (mislabeled), and the FDA has issued warnings against such products. For reconstitution guidance, use our peptide reconstitution calculator.

The decision framework is straightforward once you weigh metabolic risk against convenience.

Stacking MK-677 with ipamorelin is not recommended. Both target the ghrelin receptor, making the combination redundant rather than synergistic. You double the ghrelin pathway stimulation without adding a complementary mechanism.

The additive effect on appetite and water retention would be pronounced. Insulin resistance risk from MK-677 would persist regardless of what you stack with it.

Better stacks exist. Ipamorelin pairs with CJC-1295 (a GHRH analog) to activate two distinct pathways: GHRH receptor plus ghrelin receptor. This creates genuine synergy. MK-677 is best used alone or cycled separately from ipamorelin. For stacking guidance, see our peptide stacking guide.

Both compounds require monitoring, but MK-677 demands more frequent glucose checks.

Stop MK-677 immediately if: fasting glucose exceeds 126 mg/dL on two consecutive readings, fasting insulin doubles from baseline, or you develop lower extremity edema that does not resolve with hydration and sodium reduction.

Stop ipamorelin if: severe persistent headaches develop, joint pain limits daily function, or IGF-1 exceeds the upper reference range.

For comprehensive safety protocols, see our peptide safety guide.

Neither MK-677 nor ipamorelin is FDA-approved for any indication. All human data comes from Phase I/II clinical trials and clinical practice reports.

MK-677 carries specific risks that merit emphasis. A randomized trial in elderly patients recovering from hip fractures was stopped early because MK-677 subjects showed signs of congestive heart failure. The glucose and insulin sensitivity effects are consistent across multiple studies and are not dose-dependent below 25 mg/day (Nass et al., 2008).

Do not use MK-677 if you have type 2 diabetes, prediabetes, or poorly controlled fasting glucose. Do not use either compound if you have active cancer or a history of hormone-sensitive cancers without oncologist clearance. Elevated IGF-1 may theoretically promote tumor growth.

Pregnant or breastfeeding women should not use either compound. For peptides for bodybuilding comparisons and best peptides for weight loss, see our dedicated guides.